Alliance Wealth Advisors LLC UT Buys 131 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Alliance Wealth Advisors LLC UT increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,896 shares of the company’s stock after buying an additional 131 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in Medpace were worth $888,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Riverbridge Partners LLC grew its stake in shares of Medpace by 7.1% during the fourth quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock worth $199,975,000 after purchasing an additional 43,197 shares during the period. Invesco Ltd. grew its stake in shares of Medpace by 67.6% during the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after purchasing an additional 246,775 shares during the period. Wellington Management Group LLP grew its stake in shares of Medpace by 312.6% during the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after purchasing an additional 319,210 shares during the period. Northern Trust Corp grew its stake in shares of Medpace by 4.0% during the third quarter. Northern Trust Corp now owns 241,202 shares of the company’s stock worth $58,402,000 after purchasing an additional 9,192 shares during the period. Finally, AQR Capital Management LLC grew its stake in shares of Medpace by 55.7% during the third quarter. AQR Capital Management LLC now owns 183,310 shares of the company’s stock worth $44,385,000 after purchasing an additional 65,614 shares during the period. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Guggenheim lifted their price objective on Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research note on Wednesday. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and boosted their target price for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. Deutsche Bank Aktiengesellschaft initiated coverage on Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 target price for the company. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and boosted their price target for the company from $340.00 to $450.00 in a report on Tuesday. Finally, Robert W. Baird boosted their price target on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Medpace currently has a consensus rating of “Moderate Buy” and an average target price of $443.00.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the sale, the chief executive officer now owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Medpace news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the sale, the chief executive officer now owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the completion of the sale, the insider now owns 5,539,947 shares in the company, valued at approximately $2,170,274,237.25. The disclosure for this sale can be found here. Insiders have sold 189,340 shares of company stock worth $76,651,647 over the last 90 days. Company insiders own 20.30% of the company’s stock.

Medpace Stock Performance

MEDP traded up $6.16 on Friday, hitting $395.93. 144,681 shares of the company were exchanged, compared to its average volume of 240,981. Medpace Holdings, Inc. has a 12 month low of $189.30 and a 12 month high of $421.00. The company has a market cap of $12.27 billion, a PE ratio of 40.36, a PEG ratio of 1.94 and a beta of 1.38. The stock’s fifty day moving average is $397.83 and its 200-day moving average is $325.15.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.45 by $0.75. The business had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. Medpace’s revenue was up 17.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.27 earnings per share. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.